S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-κB pathway in rats

Amino Acids
Qi Hai GongYi Zhun Zhu

Abstract

Beta-amyloid (Aβ) is considered to be responsible for the pathogenesis of Alzheimer's disease (AD), and accumulation and aggregation of Aβ peptide in the brains of AD patients result in activation of glial cells which, in turn, initiates neuroinflammatory responses that involve reactive oxygen intermediates and release of inflammatory cytokines. In the present study, the protective effects of S-propargyl-cysteine (SPRC), also named as ZYZ-802, a sulphur-containing amino acid, on cognitive impairment and neuronal ultrastructure damage induced by Aβ were examined in rats, and the possible mechanisms were explored. These data showed that SPRC administration at the doses of 40, 80 mg/kg by intraperitoneal injection (i.p.) may inhibit cognitive impairment and neuronal ultrastructure damage induced by intracerebroventricular (i.c.v.) injection of 10 μg of Aβ(25-35) in rats. Subsequently, SPRC inhibited the expressions of tumor necrosis factor (TNF)-α, cyclooxygenase-2 (COX-2) mRNA, and protein in rat hippocampus. SPRC afforded a beneficial action on inhibitions of extracellular signal-regulated kinase (ERK1/2), as well as inhibitions of IκB-α degradation and activation of transcription factors of the nuclear factor κB (NF-κB) produce...Continue Reading

References

Apr 10, 1992·Science·J A Hardy, G A Higgins
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·N W KowallB A Yankner
May 1, 1984·Journal of Neuroscience Methods·R Morris
Jan 14, 1997·European Journal of Pharmacology·S DelobetteT Maurice
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·B MurrayE J Furshpan
Jun 20, 2000·Neurobiology of Aging·H AkiyamaT Wyss-Coray
Jan 11, 2001·Pharmacology & Therapeutics·K Yamada, T Nabeshima
May 2, 2002·Cell·Sankar Ghosh, Michael Karin
Oct 3, 2002·Nature Reviews. Immunology·Qiutang Li, Inder M Verma
Dec 25, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Mariona GrauperaJuan Rodés
Feb 27, 2004·Physiology & Behavior·Mikhail Yu StepanichevNatalia V Gulyaeva
Mar 3, 2004·Journal of Neural Transmission·P Eikelenboom, W A van Gool
Mar 11, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Chihiro TohdaKatsuko Komatsu
Aug 12, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Giuseppe VerdileRalph N Martins
Oct 1, 2004·The EMBO Journal·Ottavio ArancioShirley Shi Du Yan
Feb 16, 2005·Proceedings of the National Academy of Sciences of the United States of America·Giulia D'IntinoLaura Calzà
Sep 9, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jessica Koenigsknecht-Talboo, Gary E Landreth
Sep 30, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Masashi KitazawaFrank M LaFerla
Nov 23, 2005·Journal of Neurochemistry·Sabrina FlorentThierry Oster
Dec 21, 2005·Neuron·John R CirritoDavid M Holtzman
Feb 8, 2006·Journal of Neuropathology and Experimental Neurology·Brian WebsterEliezer Masliah
May 16, 2006·Neurobiology of Aging·Patrick L McGeer, Edith G McGeer
Aug 18, 2006·Journal of Alzheimer's Disease : JAD·Patrick L McGeerEdith G McGeer
Mar 31, 2007·Life Sciences·Ethika TyagiRakesh Shukla
Nov 14, 2007·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Mar 7, 2008·Neuro-degenerative Diseases·Piet EikelenboomAnnemieke J M Rozemuller
May 20, 2008·Journal of Alzheimer's Disease : JAD·Claudia Schwab, Patrick L McGeer
Jul 9, 2009·Journal of Alzheimer's Disease : JAD·Robert E Mrak
Feb 16, 2010·Neuropharmacology·Jaegyu HwangKyoungho Suk
Apr 20, 2010·Pharmacology, Biochemistry, and Behavior·Qi-Hai GongYi-Zhun Zhu

❮ Previous
Next ❯

Citations

Jun 3, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hai-Jun WeiXiao-Qing Tang
Oct 4, 2011·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Yuanting ZhengWeimin Cai
May 3, 2015·Pharmacological Reports : PR·Jerzy Bełtowski
Jul 8, 2011·The International Journal of Neuropsychopharmacology·Chuang WangHan-Ting Zhang
May 6, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kenneth R Olson
Aug 29, 2018·Oxidative Medicine and Cellular Longevity·Ya-Dan WenYi-Zhun Zhu
May 19, 2020·Evidence-based Complementary and Alternative Medicine : ECAM·Bombi LeeDae-Hyun Hahm
Mar 4, 2017·BMC Complementary and Alternative Medicine·Chatchada Sutalangka, Jintanaporn Wattanathorn
Jul 19, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Bombi LeeHyejung Lee
Nov 7, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Peter RoseYi-Zhun Zhu
Aug 8, 2017·CNS & Neurological Disorders Drug Targets·Chul Ju HwangJin Tae Hong
Jan 8, 2020·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Bombi LeeDae-Hyun Hahm

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.